Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

Triptorelin peptide icon, one bubble per amino acidTriptorelin10 residuesQHWSYWLRPGEach bubble = one amino acid. Size = residue mass. Color = chemical class.

Triptorelin

Sexual HealthFDA Approved
~3-8 hours half-life·Injection

Also known as: Decapeptyl, Trelstar, Diphereline

One case report changed how the steroid community thinks about post-cycle therapy. Triptorelin (Trelstar, Decapeptyl) is a synthetic GnRH analog, FDA-approved for prostate cancer at milligram depot doses. At a single 100 mcg injection, it does the opposite: it triggers an acute LH and FSH surge that can restart natural testosterone production. Pirola et al. (2010)[1] documented full testosterone recovery in a bodybuilder after 13 years of steroid-induced hypogonadism. The catch is real, though. A 10x dosing error turns a pituitary reset into chemical castration. This peptide tolerates zero margin for reconstitution mistakes.

What Is Triptorelin?

Triptorelin is a synthetic decapeptide analog of gonadotropin-releasing hormone with a D-tryptophan substitution at position 6 (CAS 57773-63-4). One case report defines its reputation in the peptide community: a 34-year-old bodybuilder, suppressed for over 13 years on anabolic steroids, had testosterone normalize within one month after a single 100 mcg injection (Pirola et al. 2010)[1]. That case is the entire published evidence base for triptorelin in post-cycle therapy. The modification makes it resistant to enzymatic degradation and roughly 100x greater affinity at the GnRH receptor than native GnRH. Under the brand name Trelstar, it carries FDA approval for advanced prostate cancer. Clinical uses also include endometriosis, uterine fibroids, central precocious puberty, and gender-affirming hormone therapy.

The defining characteristic is a dose-dependent paradox. A single acute pulse of 100 mcg triggers a burst of LH and FSH from the pituitary, stimulating the testes to produce testosterone. Sustained depot exposure at 3,750 mcg monthly or higher causes the opposite: receptor internalization, LH/FSH shutdown, and castrate testosterone levels. The same molecule restarts or permanently suppresses hormone production depending entirely on dose and duration. PCT users in the AAS community (r/steroids, MESO-Rx, thinksteroids.com) have adopted the single-shot protocol broadly; dozens to low hundreds of dedicated threads document bloodwork-confirmed recoveries. The evidence is thin by clinical standards (n=1) but the mechanism is pharmacologically sound.

How Triptorelin Works

Triptorelin binds GnRH receptors on gonadotroph cells in the anterior pituitary with approximately 100-fold greater binding affinity than endogenous GnRH. The D-Trp6 substitution at position 6 blocks cleavage by endopeptidases, extending receptor occupancy. On binding, it activates the same Gq/11-phospholipase C-calcium signaling cascade that native GnRH uses, forcing exocytosis of stored LH and FSH.

Timing determines everything. A single acute exposure (the 100 mcg PCT dose) produces the "flare effect." Pituitary gonadotrophs respond normally to an isolated GnRH signal. LH acts on testicular Leydig cells to produce testosterone; FSH drives Sertoli cell function and spermatogenesis. Because the peptide clears within hours (terminal half-life 2.8 to 7.6 hours per Muller et al.)[2], there is no sustained receptor occupancy and no downregulation.

Continuous exposure from depot formulations changes the picture completely. Persistent receptor activation triggers beta-arrestin-mediated GnRH receptor internalization, uncoupling of the Gq signaling pathway, and eventual receptor degradation. The pituitary becomes refractory to any GnRH stimulation. LH and FSH secretion stops. Testosterone drops below 50 ng/dL, the clinical definition of castrate levels. This suppression persists for the duration of the depot (1 to 6 months) and is the intended mechanism for prostate cancer treatment.

Triptorelin Benefits

  • Triptorelin benefits center on its unique ability to reset the hypothalamic-pituitary-testicular axis with a single injection.
  • Single 100 mcg dose triggers an acute LH/FSH surge capable of restarting testosterone production, even after years of anabolic steroid-induced suppression (Pirola et al. 2010, n=1 with 13+ years suppression)[1].
  • FDA-approved compound (Trelstar) with decades of clinical pharmacokinetic and safety data at depot doses, providing a well-characterized mechanism profile.
  • Acts directly on pituitary GnRH receptors, bypassing hypothalamic signaling deficits common in long-term AAS users whose endogenous GnRH pulse generators may be compromised.
  • One-shot protocol replaces multi-week SERM regimens. Community users report less complexity and faster timeline to testosterone normalization at weeks 4 to 6 with bloodwork confirmation.
  • Community experience across dozens to low hundreds of documented cases (r/steroids, MESO-Rx) shows consistent testosterone recovery when combined with a SERM bridge, filling the gap left by the absence of randomized controlled trial data.

Triptorelin: Science vs Community Consensus

Partially Aligned
Scientific Evidence
Weak
Based on 5 key studies·FDA-approved

Mechanism anchored to FDA depot pharmacodynamics (Trelstar label) and one case report: Pirola et al. 2010 [1], n=1.

Dosing studied: Triptorelin 100 mcg SC or IM, single shot only; get baseline LH, FSH, total T, free T, estradiol before injecting; recheck at weeks 2 and 4–6
Read the evidence (key study, limitations)

A single 100 mcg dose triggers an acute GnRH receptor pulse producing an LH/FSH flare without receptor desensitization. No PCT RCTs exist.

Key Study

Pirola et al. 2010 (PMID 20416868), n=1 case report

Limitations

Evidence base is a single case report (n=1), not an RCT. No FDA-approved 100 mcg vial in the US. 10x dosing error risks chemical castration.

Community Experience
Moderate
3.5/5
Based on dozens to low hundreds of dedicated threads in r/steroids, r/PEDS

Single-shot PCT protocol used by AAS community.

Community dosing: 100 mcg SC or IM, single shot; followed by tamoxifen 20 mg/day + clomiphene 25–50 mg/day for 30–45 days
Read the reports (what users report 4, common issues 6)

Triptorelin 100 mcg triggers LH/FSH restart. Usually combined with SERM bridge (tamoxifen + clomiphene).

What users report (4)
  • Single-shot PCT simplicity vs multi-week SERM-only regimens
  • Can restart HPTA after prolonged suppression where SERMs and HCG have both failed
  • Acts directly on pituitary: bypasses hypothalamic deficits common in long-term AAS users
  • Weeks 2–4 testosterone recovery documented in the community with bloodwork confirmation
Common issues (6)
  • Narrow margin: 10x dose error (1 mg vs 0.1 mg) risks chemical castration
  • No FDA-approved 0.1 mg US vial: users reconstitute from larger gray-market vials
  • Evidence base is a single case report, not an RCT
  • Gonadotropin refractory window post-injection can cause temporary testosterone dip; SERM follow-up required by many users
  • No quality control on research peptide supply
  • Pituitary apoplexy risk in anyone with undiagnosed pituitary adenoma (rarely screened)
Partially Aligned

Both science and community converge on 100 mcg single-dose protocol and the same mechanism (acute GnRH receptor pulse → LH/FSH flare). Diverge on evidence quality: community extrapolates broadly from one case report; clinicians have no RCT data to endorse off-label PCT use. Both agree that repeated dosing is contraindicated.

Triptorelin Dosage Guide

Case ReportTriptorelin PCT protocol from Pirola et al. case report (PMID 20416868)Source (opens in a new tab)
LevelDose / InjectionFrequency
Beginner100 mcgSingle dose
Moderate100 mcgSingle dose
Aggressive100 mcgSingle dose
Note:

The reconstitution math matters more here than with any other peptide. Getting it wrong by 10x is the difference between PCT and chemical castration. Slow down and verify.

For a 0.5 mg vial: add 5 mL bacteriostatic water. Each 1 mL drawn equals 100 mcg. That full 1 mL is your entire PCT dose. For a 1 mg vial: add 10 mL bacteriostatic water. Same result, 100 mcg per mL; draw exactly 1 mL. On a U-100 insulin syringe, that is 100 units (a full syringe).

You'll want to triple-check the vial label before reconstituting. Some research-grade 0.5 mg vials look almost identical to 1 mg vials. If you add only 1 mL of water to a 0.5 mg vial and draw the whole thing, you've just injected 500 mcg. That is 5x the target dose.

Don't split the dose. Don't save any for later. Don't repeat it. If testosterone hasn't recovered by week 6, the answer is an endocrinologist, not a second shot. Only a third-party certificate of analysis confirms what a research-grade vial holds. Pharmaceutical-grade Decapeptyl is made under regulated drug manufacturing.

Cycling

Not cycled. PCT use is a ONE-TIME single injection of 100mcg. Do not repeat. If HPTA recovery is not achieved within 4-6 weeks, reassess with bloodwork before considering any additional intervention. Repeated dosing risks pituitary desensitization.

Calculate your Triptorelin dose
Free dosage calculator with syringe visualization

Or use the universal Peptide Calculator for any peptide.

Triptorelin Protocols by Goal

intermediateCommunitySingle injection; 4–6 weeks monitoring
Single-shot pituitary reset
Wk 1 (single injection)
100 mcg · ONE TIME ONLY: do not repeat · Subcutaneous or Intramuscular
Recovery monitoring
Wk 2–6
No further triptorelin · Bloodwork at week 2 and week 4–6 · N/A

Expected: LH/FSH surge within 1–4 hours of injection; testosterone rising by week 2; normalization by week 4–6 in responders

Monitor: Baseline: LH, FSH, total T, free T, estradiol, SHBG. Recheck at weeks 2 and 4–6. If testosterone has not normalized by week 6, refer to endocrinologist.

How to Use Triptorelin

  1. 1
    Step 1

    Get baseline bloodwork before touching the vial: LH, FSH, total testosterone, free testosterone, estradiol. These values confirm you have hypogonadotropic hypogonadism (low LH/FSH) and that triptorelin is appropriate.

  2. 2
    Confirm all exogenous androgens have cleared your system

    Wait at least 2 half-lives of the longest-acting ester you were running.

  3. 3
    Reconstitute the vial

    For a 0.5 mg vial: add 5 mL bacteriostatic water slowly along the glass wall. Swirl gently. For a 1 mg vial: add 10 mL bacteriostatic water. Both give you 100 mcg per mL.

  4. 4
    Draw 1 mL (100 units on a U-100 insulin syringe)

    That is your full 100 mcg PCT dose. Verify the math one more time before injecting.

  5. 5
    Step 5

    Inject subcutaneously into the abdomen or upper thigh (27 to 31 gauge needle). Intramuscular into the deltoid is also acceptable. Both routes produce the same acute LH/FSH flare.

  6. 6
    Dispose of the remaining solution

    Do not save it for a second dose. There is no second dose.

  7. 7
    Step 7

    Recheck bloodwork at week 2 (LH, FSH, total testosterone) and again at weeks 4 to 6. Testosterone should begin rising by week 2 and normalize by week 4 to 6 in responders.

  8. 8
    Step 8

    If testosterone has not normalized by week 6, consult an endocrinologist. Do not re-inject triptorelin.

Alternative Routes

Subcutaneous (SC)

Same 100 mcg dose. SC absorption creates flip-flop kinetics (absorption rate-limited), extending effective half-life ~10x vs IV and sustaining receptor stimulation through the flare window.

Abdomen or upper thigh. 27–31 gauge insulin syringe. Draw entire volume for 100 mcg dose. Standard for community PCT use.

Intramuscular (IM)

Same 100 mcg dose. Slightly faster absorption than SC; tmax ~1–3 hours per Trelstar FDA label.

Deltoid or ventrogluteal. Either SC or IM is considered equivalent for the acute PCT flare purpose. IM is the route specified in the Trelstar label for depot formulations.

Mixing your own vial? Use the Triptorelin reconstitution calculator for the exact BAC-water-to-mcg math on any vial size.

Triptorelin Stacking Protocols

Works With

Tamoxifen (Nolvadex)

Bridges the post-triptorelin gonadotropin refractory window. Estrogen receptor antagonist at pituitary maintains LH/FSH support while testes recover. Prevents testosterone relapse observed in some triptorelin-only users.

Tamoxifen 20 mg/day starting day 1 (same day as injection), continue 30–45 days

Clomiphene (Clomid)

Additional SERM support for persistent gonadotropin suppression. Often co-administered with tamoxifen for dual-SERM coverage during the recovery window.

Clomiphene 25–50 mg/day days 1–30, concurrent with tamoxifen

Gonadorelin

Used as a less potent alternative for milder HPTA suppression before escalating to triptorelin, or as ongoing pulsatile GnRH support. Gonadorelin is generally used BEFORE or INSTEAD of triptorelin: triptorelin is the escalation when gonadorelin has been insufficient.

HCG

Most PCT protocols recommend HCG before triptorelin to prime Leydig cells for the LH surge. HCG stimulates testicular testosterone directly. Triptorelin is the escalation step when HCG has failed.

HCG 500–1,000 IU 3x/week for 2–3 weeks, then discontinue before injecting triptorelin

Avoid

Exogenous androgens (testosterone, nandrolone, etc.)

Concurrent exogenous testosterone directly suppresses HPG axis via negative feedback, negating the entire purpose of PCT. Triptorelin must be administered only after androgens have cleared.

Do not combine
GnRH antagonists (degarelix, cetrorelix)

Directly block the GnRH receptor that triptorelin must activate. Concurrent use renders triptorelin completely ineffective.

Do not combine
Dopamine agonists (cabergoline, bromocriptine)

May blunt the gonadotropin response to triptorelin. Cabergoline is common in PCT for prolactin control: time administration to minimize overlap with the acute triptorelin flare window (first 24–48 hours).

Hyperprolactinemia-inducing drugs (antipsychotics, metoclopramide)

Elevated prolactin suppresses GnRH signaling and reduces LH/FSH response to triptorelin. Normalize prolactin before injection.

Estimated Cost

Brand Price
Trelstar (triptorelin pamoate): FDA-approved US brand for prostate cancer only. 3.75 mg depot: ~$945/injection; 11.25 mg depot: ~$2,819/injection; 22.5 mg depot: ~$5,000+/injection. These are mg-range prostate cancer doses, not the 100 mcg PCT dose. No FDA-approved 100 mcg US product exists.
Generic / Research
Decapeptyl 0.1 mg/day SC (Ferring Pharmaceuticals): pharmaceutical-grade 100 mcg formulation available in Europe and other countries. NOT FDA-approved in US. ~$20/vial at international pharmacies (April 2026). Import required; regulatory status varies by country.
Compounded
No FDA-recognized compounding category for triptorelin PCT doses. Unregulated gray-market research-grade product: ~$47–$94 per 0.5 mg vial (April 2026). Users reconstitute and draw down to 100 mcg. No quality guarantee: high quality risk.

Pricing updated 2026-04-09

Triptorelin Side Effects

The most dangerous risk with triptorelin is not a side effect. It is a dosing error. A single injection of 1 mg instead of 0.1 mg (a 10x miscalculation during reconstitution) can trigger the same pituitary receptor downregulation used therapeutically in prostate cancer. The result is prolonged chemical castration from what was supposed to be a PCT dose. This margin is not forgiving.

At the correct 100 mcg PCT dose, published and community-reported side effects are generally mild and transient. Hot flushes occur in the hours following injection as the LH/FSH surge drives a rapid testosterone spike. Headache, nausea, and injection site pain are common (greater than 10% incidence based on Trelstar label extrapolation). Some users report temporary acne or mood volatility in the first 3 to 5 days, attributed to the initial testosterone flare.

A less obvious risk is the gonadotropin refractory window. After the acute LH/FSH flare, gonadotropin levels can dip temporarily before stabilizing. Users who skip the SERM bridge (tamoxifen, clomiphene) sometimes report testosterone normalization followed by a relapse at weeks 2 to 4. This is not a direct side effect of triptorelin but a predictable pharmacodynamic consequence that the community figured out before any formal study documented it.

Pituitary apoplexy is the rarest but most severe risk. Anyone with an undiagnosed pituitary adenoma faces the possibility of hemorrhage or infarction triggered by the acute LH/FSH surge. Symptoms include sudden severe headache, vision changes, nausea, and altered consciousness. This is a medical emergency. The Trelstar FDA label explicitly warns about this risk. A pituitary MRI before injection is the prudent screening step, though almost nobody in the community actually gets one.

At depot/clinical doses (milligram range, not applicable to PCT): hot flashes, erectile dysfunction, decreased libido, bone density loss, mood disturbances, and tumor flare in prostate cancer patients during the first 1 to 2 weeks are expected and well-documented.

Contraindications: hormone-sensitive cancers (unless under oncologist supervision), pregnancy (Category X, causes fetal harm), primary hypogonadism (pituitary stimulation cannot help if testes cannot respond), known hypersensitivity to GnRH analogs, and concurrent GnRH agonist or antagonist therapy.

Stop and seek medical attention immediately if you experience sudden severe headache, vision problems, or altered consciousness after injection.

Common Issues & Solutions

No testosterone recovery by week 4–6: check LH/FSH: if both are high post-injection but T is still low, this is primary hypogonadism (Leydig cell failure); triptorelin cannot help. Refer to endocrinologist. If LH/FSH also remain low, possible pituitary failure or undetected adenoma.

Testosterone normalizes then relapses at weeks 2–4: classic post-flare refractory window issue. If SERM bridge was not used, add tamoxifen 20 mg/day retrospectively and recheck at week 6.

Temptation to re-dose due to slow recovery: DO NOT repeat the injection. A second dose initiates receptor desensitization. Wait the full 6 weeks and get bloodwork before any further intervention. Re-dosing risks prolonged chemical castration.

Dosing error during reconstitution: 0.1 mg and 1 mg differ by 10x. If reconstituting a 0.5 mg vial with 5 mL BAC water, 1 mL = 100 mcg (correct PCT dose). If reconstituting a 1 mg vial with 10 mL BAC water, 1 mL = 100 mcg. Verify math before every injection.

Sudden severe headache, vision changes, or altered consciousness after injection: possible pituitary apoplexy (hemorrhage into undiagnosed pituitary adenoma triggered by the LH/FSH surge). This is a medical emergency: call emergency services immediately.

Ask AI about this page

Ask AI for a second opinion on Triptorelin dosing and side effects

Contraindications

  • Hormone-sensitive cancers (unless under oncologist supervision at depot doses)
  • Pregnancy: causes fetal harm (Category X)
  • Primary hypogonadism: pituitary stimulation will not help if testes cannot respond
  • Known hypersensitivity to GnRH analogs or any component of the formulation
  • Do not use if already on GnRH agonist/antagonist therapy

Drug Interactions

  • Androgens: concurrent exogenous testosterone negates the purpose of PCT stimulation
  • GnRH antagonists (degarelix, cetrorelix): directly block the receptor triptorelin needs to activate
  • Dopamine agonists (cabergoline, bromocriptine): may blunt gonadotropin response
  • Hyperprolactinemia-inducing drugs: elevated prolactin suppresses GnRH signaling
  • Directly block the GnRH receptor that triptorelin must activate. Concurrent use renders triptorelin completely ineffective.

Product Quality

Recommended Monitoring

TestWhenTarget
Total testosteroneBaseline (before injection); week 2; week 4–6400–900 ng/dL (normal adult male)
LH and FSHBaseline; week 2; week 4–6LH: 1.7–8.6 IU/L; FSH: 1.5–12.4 IU/L
Estradiol (E2)Baseline; week 4–620–40 pg/mL (physiologic male)
Free testosteroneBaseline; week 4–69–30 ng/dL (age-dependent)
ProlactinBaseline (especially if using dopaminergic drugs or antipsychotics)<15 ng/mL (male reference)
Pituitary MRI (sella turcica)Before injection: ideal but rarely performed in community PCT usersNot listed
Total testosterone

Primary endpoint: confirms whether triptorelin successfully restarted Leydig cell steroidogenesis

LH and FSH

Elevated LH/FSH at baseline = primary hypogonadism (triptorelin inappropriate). Low LH/FSH at baseline = hypogonadotropic (triptorelin correct target). Post-injection LH/FSH should flare then normalize.

Estradiol (E2)

Confirms testosterone is rising (E2 rises with T via aromatization). Excessive E2 elevation may require aromatase inhibitor management.

Free testosterone

More sensitive than total T for borderline recovery cases; useful if SHBG is elevated

Prolactin

Hyperprolactinemia suppresses GnRH signaling and blunts triptorelin effectiveness. Normalize before injection.

Pituitary MRI (sella turcica)

Rules out undiagnosed pituitary adenoma. Acute LH/FSH surge from triptorelin can trigger pituitary apoplexy (hemorrhage/infarction) in adenoma patients: a medical emergency. Explicitly cited in the Trelstar FDA label.

Triptorelin Before and After

Hours 1-4

Acute LH and FSH surge measurable on bloodwork. Triptorelin reaches peak plasma concentration within 1-3 hours.

Days 1-7

LH and FSH remain elevated from the initial flare. Testes begin responding to gonadotropin stimulation.

Week 2

Testosterone levels start rising as Leydig cells resume steroidogenesis. Early subjective improvements in energy and mood possible.

Week 4-6

Full HPTA recovery expected if pituitary and testes are functional. Testosterone should be in normal range on labs. Libido and energy normalized.

What to Expect

Hours 1 to 4: Triptorelin reaches peak plasma concentration within 1 to 3 hours after injection (Trelstar FDA label). LH and FSH levels surge measurably on bloodwork within this window. Some users report a brief flush of energy or mild libido bump; most feel nothing acutely. Transient hot flush, headache, or nausea can occur.

Days 1 to 7: LH and FSH remain raised from the initial flare. Leydig cells in the testes begin responding to gonadotropin stimulation and initiating steroidogenesis. Subjective changes are minimal during week 1. Users who skipped the SERM bridge sometimes notice a gonadotropin dip around days 5 to 7 as the refractory window opens. Mild transient acne is possible from the testosterone flare.

Week 2: Testosterone levels start climbing as Leydig cells resume full steroidogenesis. Bloodwork at this point should show measurable improvement. Most responding users report better energy, improved mood, and early libido return. No change at week 2 doesn't mean failure; weeks 4 to 6 are the true endpoint.

Weeks 4 to 6: The expected finish line. In pituitary- and gonad-competent individuals, full HPTA recovery should be confirmed on labs. Testosterone within normal range, LH and FSH normalized. The majority of successful community cases report bloodwork-confirmed testosterone normalization by this point. Users who ran the SERM bridge report more consistent recovery compared to standalone triptorelin protocols. No side effects expected if recovery is progressing normally.

Detailed Timeline: Science vs Community

Hours 1–4
Science

Triptorelin reaches peak plasma concentration within 1–3 hours (IM, Trelstar label). Measurable LH and FSH surge on bloodwork within 1–4 hours of injection.

Community

Some users report heightened energy or mild libido within hours, attributed to the testosterone flare effect. Most notice nothing acutely.

Days 1–7
Science

LH and FSH remain elevated. Testes begin responding to gonadotropin stimulation. Leydig cells initiate steroidogenesis.

Community

Limited subjective change in week 1. Some report mild mood improvement. Users without SERM bridge may notice a gonadotropin dip around days 5–7 (refractory window).

Week 2
Science

Testosterone levels start climbing as Leydig cells resume steroidogenesis. Bloodwork at week 2 should show measurable improvement.

Community

Most responding users report improved energy, mood, and early libido return. No change at week 2 is not definitive failure: week 4–6 is the true endpoint.

Weeks 4–6
Science

Full HPTA recovery in pituitary- and gonad-competent individuals. Testosterone within normal range. LH/FSH normalized.

Community

Majority of successful cases report testosterone normalization confirmed by bloodwork. SERM bridge users report more consistent recovery vs standalone triptorelin.

Pharmacokinetics

Half-Life
7.6h
Bioavailability
IM depot: ~38% over 13 days; SC single dose: not formally quantified
Tmax
1-3 hours (IM, from Trelstar FDA label)
Data Confidence
high

Source: Muller et al. 1997 (PMID 9354307): terminal t½ 2.8h in healthy males, 6.6-7.7h in renal/hepatic impairment; SC bioavailability extends effective t½ ~10x vs IV per Lahlou 2005 (PMID 16302716)

Molecular Profile

Amino Acids
10
Sequence
QHWSYWLRPG
HydrophobicPolarPositiveNegativeSpecialHow we generate these icons
Identifiers
CAS: 57773-63-4 (free base)PubChem 25074470 (opens in a new tab)

Who Should Consider Triptorelin

  • Men in post-cycle therapy after anabolic steroid use
  • Men with prolonged hypogonadotropic hypogonadism from exogenous androgens
  • Clinicians managing steroid-induced HPTA suppression
  • Prostate cancer patients (at depot doses: different use case)

Related Peptides

What Changed for Triptorelin

No material change since Oct 5, 2026. Checked against Federal Register, openFDA Drugs@FDA, openFDA drug labels, openFDA enforcement reports and PubMed retraction links on Oct 14, 2026. How the change record works

Peptide Schedule Research TeamReviewed Apr 7, 20265 Citations

References

  1. [1]Anabolic steroids purchased on the Internet as a cause of prolonged hypogonadotropic hypogonadism (opens in a new tab)PubMed (opens in a new tab)PubMed
  2. [2]Pharmacokinetics of triptorelin after intravenous bolus administration in healthy males and in males with renal or hepatic insufficiency (opens in a new tab)PubMed (opens in a new tab)PubMed

Related Tools

Storage & Stability

Before Reconstitution
Room temperature up to 30 days, refrigerated up to 2 years
After Reconstitution
Refrigerate at 2-8°C, use within 24 hours (single-use vial)
Temperature
2-8°C (36-46°F) recommended

Frequently Asked Questions

Based on the Pirola 2010 case report (PMID 20416868), yes: a 34-year-old with 13+ years of steroid use had testosterone normalize within one month after a single 100 mcg injection, even after conventional PCT (HCG + clomiphene) had already failed. But it's one case report, not a clinical trial. It works because one acute GnRH pulse triggers an LH/FSH flare without causing the receptor shutdown that comes from sustained exposure.

The PCT dose is 0.1 mg; the monthly prostate cancer depot is 3,750 mg: a 37,500-fold difference. But the distinction isn't just dose size; it's duration of receptor occupancy. The single shot clears in hours. Depot formulations release drug continuously for months. A single dose of just 1 mg (1,000 mcg) sustained long enough can cause shutdown. The margin for error is narrow in absolute micrograms.

After the initial LH/FSH surge from triptorelin, there's a natural refractory period where gonadotropin levels can dip before stabilizing. Some users start tamoxifen (20 mg/day) or clomiphene on the same day to maintain support through this window. Without SERM follow-up, some people report testosterone normalization followed by a relapse 2-4 weeks post-injection.

Not as an FDA-approved product. The Decapeptyl 0.1 mg daily SC formulation is a Ferring product available in Europe and other countries, but not FDA-approved in the US. People using triptorelin for PCT in the US typically use imported pharmacy product or research-grade vials, reconstituting larger vials and drawing down to 100 mcg.

Pituitary apoplexy is sudden hemorrhage or infarction of the pituitary gland. It can happen when a GnRH agonist triggers a rapid LH/FSH surge in someone with an undiagnosed pituitary adenoma. The acute hormone surge increases blood flow, which can cause the adenoma to bleed. Symptoms: sudden severe headache, vision problems, nausea, altered consciousness: a medical emergency. This risk applies even at the PCT dose. Anyone considering triptorelin should ideally get a pituitary MRI first, though almost nobody in the community actually does.